These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7467397)

  • 1. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.
    Islam SI; Idle JR; Smith RL
    Xenobiotica; 1980 Nov; 10(11):819-25. PubMed ID: 7467397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population.
    Mbanefo C; Bababunmi EA; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Xenobiotica; 1980 Nov; 10(11):811-8. PubMed ID: 7467396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic hydroxylation of Debrisoquine in man.
    Mahgoub A; Idle JR; Dring LG; Lancaster R; Smith RL
    Lancet; 1977 Sep; 2(8038):584-6. PubMed ID: 71400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
    Alván G; Grind M; Graffner C; Sjöqvist F
    Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
    Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G
    Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
    Mahgoub A; Idle JR; Smith RL
    Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylation polymorphism in diabetic patients.
    Kallio J; Huupponen R; Viikari J
    Diabetes Res; 1990 Nov; 15(3):125-9. PubMed ID: 2132205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the frequency distribution of debrisoquine hydroxylation deficiency in Chinese healthy Zang and Wei volunteers].
    Kuang TY; Liao XM; Wang KY; Zhang Y; Lou YQ
    Yao Xue Xue Bao; 1991; 26(4):250-4. PubMed ID: 1957669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
    Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
    Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
    Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
    Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
    Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.